Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing

Abstract Aims/Introduction A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings from the summative usability testing process for...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	David C Klonoff, Stephanie Bassock, Andrea Dwyer, Ella Engels, Marianne Qvist, Thomas Sparre, Soren Snitker
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2021-06-01
Ráidu:	Journal of Diabetes Investigation
Fáttát:	Glucagon‐like peptide‐1 receptor agonist Human factors engineering Pen‐injector
Liŋkkat:	https://doi.org/10.1111/jdi.13429
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!